Sodium Bicarbonate Injection Recalled Due to Sterility Assurance Issue
Exela Pharma Sciences is recalling Sodium Bicarbonate 8.4% Injection due to lack of sterility assurance. The recall affects approximately 103,950 vials nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II with lack of sterility assurance in an injectable product constitutes a risk-of-harm where injury has not been reported. Per the rubric, such products score 3. The theoretical nature of the hazard and absence of reported illnesses preclude a higher score.
Plain-English summary
Exela Pharma Sciences LLC is recalling Sodium Bicarbonate 8.4% Injection, USP, in 50 mL single-dose vials (1 mEq/mL). The affected lots are 10006417 and 10006418, with an expiration date of November 30, 2026.
The recall is due to lack of assurance of sterility for the affected lots.
Approximately 103,950 vials were distributed nationwide.
The recalled product
- Product
- SODIUM BICARBONATE (SODIUM BICARBONATE)
- Brand
- SODIUM BICARBONATE
- Manufacturer
- Exela Pharma Sciences LLC
- Category
- Drug — Injectable
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: 10006417 and 10006418
- Exp. 11/30/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · SODIUM BICARBONATE
- HighFDA Recalls Sodium Bicarbonate Injection Due to Arsenic Contamination
FDA (Drugs) · 2025-09-17
- HighPfizer Recalls Sodium Bicarbonate Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2025-08-27
- SevereFDA Recalls Sodium Bicarbonate Injection Due to Glass Particle Contamination
FDA (Drugs) · 2024-01-24
- SevereFDA Recalls Sodium Bicarbonate Injection for Silicone Particulate Contamination
FDA (Drugs) · 2023-11-29
- SevereFDA Recalls Sodium Bicarbonate Injection for Defective Vials
FDA (Drugs) · 2022-12-21
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27